Trials / Completed
CompletedNCT00159718
Double Blind Atorvastatin Amlodipine Study
Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 360 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia. Amlodipine's use in angina has been well documented in clinical trials such as the Circadian Anti-Ischemia Program in Europe (CAPE), but the impact on vascular inflammation in clinical practice has not been tested. Furthermore, the potentially synergistic benefit of atorvastatin and amlodipine on inflammation ischemic activity has not been studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | amlodipine | |
| DRUG | atorvastatin |
Timeline
- Start date
- 2001-07-01
- Completion
- 2007-01-01
- First posted
- 2005-09-12
- Last updated
- 2021-01-28
Locations
33 sites across 11 countries: Croatia, Czechia, Estonia, Hungary, Latvia, Norway, Poland, Romania, Slovakia, South Africa, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00159718. Inclusion in this directory is not an endorsement.